Clinical Research Directory
Browse clinical research sites, groups, and studies.
LRFN5 and OLFM4 in Methamphetamine-Induced Psychosis
Sponsor: Elazığ Mental Health and Diseases Hospital
Summary
This cross-sectional observational case-control study aimed to examined serum levels of leucine-rich repeat and fibronectin type III domain-containing protein 5 (LRFN5) and olfactomedin-4 (OLFM4) levels in methamphetamine use disorder (MUD), methamphetamine-induced psychotic disorder (MP), and healthy control (HC) groups. The study also aimed to assessed systemic inflammation using the Aggregate Index of Systemic Inflammation (AISI) and examined associations between biomarkers and clinical symptom severity, including Insight Assessment Scale (IAS) and Positive and Negative Syndrome Scale (PANSS) scores.
Official title: Serum LRFN5 and OLFM4 Levels in Methamphetamine Use Disorder and Methamphetamine-Induced Psychotic Disorder: A Cross-Sectional Case-Control Study
Key Details
Gender
MALE
Age Range
18 Years - 49 Years
Study Type
OBSERVATIONAL
Enrollment
120
Start Date
2025-09-01
Completion Date
2026-04-01
Last Updated
2026-03-04
Healthy Volunteers
Yes
Locations (1)
Elazığ Mental Health and Diseases Hospital
Elâzığ, Elâzığ, Turkey (Türkiye)